14 results about "Trimetazidine" patented technology

Methods of using small molecule inhibitors of fatty acid oxidation (FAO) as antimicrobials against intracellular Mycobacteria are disclosed. FAO inhibitors including etomoxir, trimetazidine, oxfenicine perhexeline and / or can be used alone, or in combination with known as antimycobacterial agents against intracellular Mycobacteria.

The invention relates to the field of biological medicines, and discloses application of gynostemma pentaphylla exosomes in preparation of myocardial protection medicines. The medicine comprises a medicine for treating myocardial injury after myocardial infarction; a drug for improving myocardial cell dysfunction in a sub-health state; and myocardial health-care drugs. According to the application, the myocardial protection effect of the gynostemma pentaphyllum exosome is found for the first time, and in a rat myocardial infarction reperfusion model, the gynostemma pentaphyllum exosome remarkably inhibits and reduces cell apoptosis and down-regulates alpha-SMA expression, and blocks a myocardial deterioration process. The recovery effect on the heart function is equivalent to that of a small molecular medicine trimetazidine, and is obviously better than that of gypenoside.

The invention relates to an isotope labeled trapidil derivative. In particular, isotope labeled trapidil derivatives useful in the treatment of Parkinson's disease and dyskinesia associated with Parkinson's disease are provided. The isotope labeled trapidil derivative comprises a deuterated trapidil derivative. In addition, combination therapies of isotopically labeled trapidil derivatives and additional therapeutic agents for the treatment of Parkinson's disease and dyskinesia associated with Parkinson's disease are also provided.

This invention belongs to the field of small molecule pharmaceutical compounds and relates to the application of trimetazidine in the preparation of drugs for treating glycogen storage diseases. This invention provides a novel treatment strategy for glycogen storage diseases, discovering that the small molecule compound trimetazidine can reduce the load on lysosomal pathways, further reducing cellular glycogen accumulation, thus achieving a therapeutic effect on glycogen storage diseases. In animal experiments, observations of skeletal muscle movement in mice confirmed that trimetazidine significantly enhances muscle function and strength in mice with glycogen storage diseases. Therefore, trimetazidine can be used clinically for the prevention or treatment of glycogen storage diseases, and possesses the advantages of small molecular weight, oral administration, and low cost for industrialization.

The present invention relates to a coated tablet composition comprising trimetazidine (KN713) and a process for the preparation thereof. In the invention, in order to improve the flowability of an active ingredient trimetazidine of a KN713 tablet (30mg), silicified microcrystalline cellulose, mannitol and colloidal silicon dioxide are used to design a tablet composition, and magnesium stearate is added to solve a film forming phenomenon occurring in a tabletting process. Furthermore, when a KN713 tablet (30 mg) is produced using the coated tablet composition of the present invention, it is confirmed that a tablet conforming to disintegration, dissolution, and friability standards can be produced, and the increase in related substances is significantly reduced. Therefore, the tablet composition of the present invention can be effectively used as an anticancer tablet.

This invention provides a method for preventing, mitigating, and / or treating contrast-induced acute kidney injury. [Solution] In one embodiment, a method is provided for preventing, mitigating and / or treating contrast-induced acute kidney injury, comprising administering a fatty acid oxidation inhibitor to a patient in need thereof. The method also provides for the use of trimetazidine or a pharmaceutically acceptable salt thereof for the prevention and / or treatment of contrast-induced acute kidney injury. The method also provides for administering one or more of the following: trimetazidine, etomoxyl, oxphenicin, perhexylline, mildronate, or lanolazine, or a pharmaceutically acceptable salt thereof. This invention provides a method for preventing and / or treating nephropathy.

The present application belongs to the field of disease prevention and treatment and aquaculture technology, and relates to application of trimetazidine in preparation of broad-spectrum antiviral drugs for aquaculture. The present application proves through tests that trimetazidine can inhibit WSSV and DIV-1 genomic mRNA transcription and replication of complete virions, improve the survival rate of shrimp and other aquatic animals after being infected with WSSV and DIV-1, and relieve the invasion of viruses on shrimp and other aquatic animals. Therefore, trimetazidine can endow shrimp and other aquatic animals with certain antiviral ability, so as to ensure the healthy development of shrimp and other aquatic animal breeding industry.

The invention belongs to the technical field of disease prevention and treatment and aquaculture, and relates to application of trimetazidine in preparation of a broad-spectrum antiviral drug for aquaculture. Tests prove that trimetazidine can inhibit mRNA transcription of WSSV and DIV-1 genomes and replication of complete virions, improve the survival rate of aquatic animals such as prawns after being infected with WSSV and DIV-1, and relieve invasion of viruses to the aquatic animals such as prawns. Therefore, trimetazidine can endow prawns and other aquatic animals with certain antiviral ability, thereby ensuring the healthy development of the breeding industry of prawns and other aquatic animals.

This invention relates to a novel trimetazidin solid phase that reduces the formation of trimetazidin nitrosamines in the presence of nitrites.

The invention provides methods of treatment of heart failure with preserved ejection fraction (HFpEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of a pharmaceutical composition in the treatment of moderate fatty liver. This invention provides a combination of levocarnitine and trimetazidine, which, through the synergistic effect of levocarnitine and trimetazidine, treats moderate non-alcoholic fatty liver from the perspective of fat and glucose metabolism, thereby achieving its application in the treatment of moderate fatty liver.

To provide a method for enhancing metabolic efficiency of the heart SOLUTION: Compositions and methods for increasing metabolic efficiency of the heart are provided. The present invention provides compositions that stimulate cardiac glucose oxidation and mitochondrial respiration. The composition comprises a compound that shifts cardiac metabolism from fatty acid oxidation to glucose oxidation, such as trimetazidine, and a compound that promotes mitochondrial respiration, such as succinate. The compositions may also include molecules such as nicotinic acid, which serves as a precursor for nicotinamide adenine dinucleotide (NAD +) synthesis and also facilitates mitochondrial respiration. Preferably, the composition comprises a compound in which the trimetazidine derivative, the succinate and optionally the NAD + precursor are covalently linked in a single molecule.SELECTED DRAWING: Figure 1

This invention belongs to the pharmaceutical field, specifically relating to a compound pharmaceutical preparation for treating chronic uric acid nephropathy and its application. This invention provides a compound pharmaceutical preparation for treating chronic uric acid nephropathy, which is a tablet composed of levocarnitine and trimetazidine in a certain proportion. The levocarnitine and trimetazidine compound preparation can significantly improve renal function in patients with chronic uric acid nephropathy and protect against kidney damage.